About Gradient Denervation Technologies
Gradient Denervation Technologies is a company based in Paris (France) founded in 2020.. Gradient Denervation Technologies has raised $19.16 million across 3 funding rounds from investors including EIT Health, Asabys Partners and Thuja Capital. Gradient Denervation Technologies offers products and services including Pulmonary Artery Denervation System. Gradient Denervation Technologies operates in a competitive market with competitors including Pulmonx, Neurent Medical, Spiration, Uptake Medical and Emphasys Medical, among others.
- Headquarter Paris, France
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$19.16 M (USD)
in 3 rounds
-
Latest Funding Round
$15.02 M (USD), Series A
Sep 07, 2023
-
Investors
EIT Health
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Gradient Denervation Technologies
Gradient Denervation Technologies offers a comprehensive portfolio of products and services, including Pulmonary Artery Denervation System. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Minimally-invasive catheter for treating pulmonary hypertension in heart failure patients.
Unlock access to complete
Software Development Team
1 people
Leadership Team
1 people
COO Team
1 people
Product Management Team
1 people
Unlock access to complete
Funding Insights of Gradient Denervation Technologies
Gradient Denervation Technologies has successfully raised a total of $19.16M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $15.02 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $15.0M
-
First Round
First Round
(01 Feb 2020)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2023 | Amount | Series A - Gradient Denervation Technologies | Valuation | Asabys Partners | |
| Jun, 2020 | Amount | Grant - Gradient Denervation Technologies | Valuation |
investors |
|
| Feb, 2020 | Amount | Seed - Gradient Denervation Technologies | Valuation | Sofinnova Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Gradient Denervation Technologies
Gradient Denervation Technologies has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include EIT Health, Asabys Partners and Thuja Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Early-stage centric life sciences focused VC firm funding in Netherlands, Belgium and the US
|
Founded Year | Domain | Location | |
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Gradient Denervation Technologies
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Gradient Denervation Technologies
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Gradient Denervation Technologies Comparisons
Competitors of Gradient Denervation Technologies
Gradient Denervation Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Pulmonx, Neurent Medical, Spiration, Uptake Medical and Emphasys Medical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of smart devices for treating pulmonary diseases
|
|
| domain | founded_year | HQ Location |
Smart devices for minimally invasive rhinitis treatment are developed.
|
|
| domain | founded_year | HQ Location |
IntraBronchial Valve to treat lung disease
|
|
| domain | founded_year | HQ Location |
Targeted vapor therapy is developed for endoscopic lung volume reduction.
|
|
| domain | founded_year | HQ Location |
Endobronchial valves for emphysema treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Gradient Denervation Technologies
Frequently Asked Questions about Gradient Denervation Technologies
When was Gradient Denervation Technologies founded?
Gradient Denervation Technologies was founded in 2020.
Where is Gradient Denervation Technologies located?
Gradient Denervation Technologies is headquartered in Paris, France.
Who is the current CEO of Gradient Denervation Technologies?
Martin Grasse is the current CEO of Gradient Denervation Technologies.
Is Gradient Denervation Technologies a funded company?
Gradient Denervation Technologies is a funded company, having raised a total of $19.16M across 3 funding rounds to date. The company's 1st funding round was a Seed of $4.14M, raised on Feb 01, 2020.
What does Gradient Denervation Technologies do?
Gradient Denervation Technologies was founded in 2020 and is based in Paris, France. Operations focus on the medical device sector, where endovascular, catheter-based solutions are developed to address pulmonary hypertension. Therapy is offered to reduce pulmonary vascular resistance and enhance cardiovascular hemodynamics. The company is led by CEO Martin Grasse, with activities centered on innovative treatments for cardiovascular conditions.
Who are the top competitors of Gradient Denervation Technologies?
Gradient Denervation Technologies's top competitors include Pulmonx, Neurent Medical and Spiration.
What products or services does Gradient Denervation Technologies offer?
Gradient Denervation Technologies offers Pulmonary Artery Denervation System.
Who are Gradient Denervation Technologies's investors?
Gradient Denervation Technologies has 4 investors. Key investors include EIT Health, Asabys Partners, Thuja Capital, and Sofinnova Partners.